A study of MN-166 (ibudilast) in ALS
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Ibudilast (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 25 Sep 2018 According to a MediciNova media release, the company has received a positive feedback from the FDA regarding the Phase III clinical development plan for MN-166 in ALS. The Company has received approval from FDA to proceed with Phase III development of MN-166 for ALS and will finalize the study design according to FDA's feedback.
- 13 Jul 2018 New trial record
- 09 Jul 2018 According to a MediciNova media release, the company has requested a meeting with the FDA to discuss the study design.